Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

240.83
-5.0400-2.05%
Volume:702.58K
Turnover:169.64M
Market Cap:15.63B
PE:16.46
High:246.81
Open:246.81
Low:239.84
Close:245.87
52wk High:266.38
52wk Low:124.47
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.25
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.26
PE(LYR):-41.24

Loading ...

Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says

MT Newswires Live
·
Aug 28

RBC Raises Price Target on Jazz Pharmaceuticals to $299 From $277, Keeps Outperform Rating

MT Newswires Live
·
Aug 28

Jazz Pharmaceuticals Plc : RBC Raises Target Price to $299 from $277

THOMSON REUTERS
·
Aug 28

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Reuters
·
Aug 28

Jazz Pharmaceuticals prices upsized $1.1B offering of exchangeable senior notes

TIPRANKS
·
Aug 27

Jazz Pharmaceuticals (JAZZ) Stock May Be Undervalued As FDA Cancer Approval Lands

Simply Wall St.
·
Aug 27

Jazz Pharmaceuticals Prices Upsized $1.1 Billion Senior Notes Offering

MT Newswires Live
·
Aug 27

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 27

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT Newswires Live
·
Aug 27

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 27

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals price target raised to $281 from $264 at Truist

TIPRANKS
·
Aug 26

Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes Due 2032 and Concurrent Ordinary Share Repurchases

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Initial Purchasers May Buy up to $150 Mln Additional Notes

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Expects to Repurchase up to $225 Mln of Ordinary Shares Concurrently

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Net Proceeds from Offering Expected to be Used for General Corporate Purposes

THOMSON REUTERS
·
Aug 26

Piper Sandler Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 26

RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Highlights Ziihera Launch, Targets $3-$5 Billion Zanidatamab Peak Sales Opportunity

Reuters
·
Aug 26